These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9307256)

  • 1. Short- and long-duration responses to levodopa during the first year of levodopa therapy.
    Nutt JG; Carter JH; Van Houten L; Woodward WR
    Ann Neurol; 1997 Sep; 42(3):349-55. PubMed ID: 9307256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of the response to levodopa during the first 4 years of therapy.
    Nutt JG; Carter JH; Lea ES; Sexton GJ
    Ann Neurol; 2002 Jun; 51(6):686-93. PubMed ID: 12112073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease.
    Zappia M; Colao R; Montesanti R; Rizzo M; Aguglia U; Gambardella A; Oliveri RL; Quattrone A
    Ann Neurol; 1997 Aug; 42(2):245-8. PubMed ID: 9266736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
    Nutt JG; Carter JH; Carlson NE
    Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The subacute levodopa test for evaluating long-duration response in Parkinson's disease.
    Quattrone A; Zappia M; Aguglia U; Branca D; Colao R; Montesanti R; Nicoletti G; Palmieri A; Parlato G; Rizzo M
    Ann Neurol; 1995 Sep; 38(3):389-95. PubMed ID: 7668824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
    Zappia M; Nicoletti A; Muñoz-S D; Tapia-Núñez J
    Rev Neurol; 2009 Jul 1-15; 49(1):33-40. PubMed ID: 19557698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease.
    McColl CD; Reardon KA; Shiff M; Kempster PA
    Mov Disord; 2002 Nov; 17(6):1227-34. PubMed ID: 12465061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications.
    Anderson E; Nutt J
    Parkinsonism Relat Disord; 2011 Sep; 17(8):587-92. PubMed ID: 21530356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease.
    Bastian AJ; Kelly VE; Perlmutter JS; Mink JW
    Mov Disord; 2003 Sep; 18(9):1008-17. PubMed ID: 14502668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal study of the motor response to levodopa in Parkinson's disease.
    Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA
    Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-duration response to levodopa in patients with advanced Parkinson disease treated with subthalamic deep brain stimulation.
    Wider C; Russmann H; Villemure JG; Robert B; Bogousslavsky J; Burkhard PR; Vingerhoets FJ
    Arch Neurol; 2006 Jul; 63(7):951-5. PubMed ID: 16831963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.
    Zappia M; Montesanti R; Colao R; Branca D; Nicoletti G; Aguglia U; Quattrone A
    Mov Disord; 1997 Jan; 12(1):103-6. PubMed ID: 8990062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa induced motor complications in Thai Parkinson's disease patients.
    Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
    J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dopamine transporter: importance in Parkinson's disease.
    Nutt JG; Carter JH; Sexton GJ
    Ann Neurol; 2004 Jun; 55(6):766-73. PubMed ID: 15174010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
    Antonini A; Isaias IU; Canesi M; Zibetti M; Mancini F; Manfredi L; Dal Fante M; Lopiano L; Pezzoli G
    Mov Disord; 2007 Jun; 22(8):1145-9. PubMed ID: 17661426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
    Muhlack S; Woitalla D; Welnic J; Twiehaus S; Przuntek H; Müller T
    Neurosci Lett; 2004 Jun; 363(3):284-7. PubMed ID: 15182961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motivational Vigor in Parkinson's Disease Requires the Short and Long Duration Response to Levodopa.
    Brissenden JA; Scerbak T; Albin RL; Lee TG
    Mov Disord; 2024 Jan; 39(1):76-84. PubMed ID: 38062630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.